Galera(GRTX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates General Corporate Updates First Quarter 2024 Financial Highlights • Research and development expenses were $1.5 million in the first quarter of 2024, compared to$7.3 million for the same period in 2023. The decrease was primarily attributable to a decrease in avasopasem and rucosopasem development costs. The Company has ceased all clinical trial activity and suspended the clinical development of its product candid ...